Pathological involvement of astrocyte-derived lipocalin-2 in the demyelinating optic neuritis

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 6, 2015, Pages 3691-3698

  Chun, Bo Young ^a   Kim, Jong Heon ^a   Nam, Youngpyo ^a   Huh, Man Il ^b   Han, Seungwoo ^c   Suk, Kyoungho ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Biomedical Research Institute Kyungpook National University Hospital ^*  (South Korea)

Author keywords

Astrocyte; Experimental autoimmune encephalomyelitis; Lipocalin 2; Microglia; Neuroinflammation; Optic neuritis

Indexed keywords

LIPOCALIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STEROID; TOLL LIKE RECEPTOR; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY ASSESSMENT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GLIOSIS; HUMAN; IMMUNOFLUORESCENCE; INFLAMMATION; MALE; MICROGLIA; MOUSE; NONHUMAN; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DEMYELINATING DISEASES; METABOLISM; PHYSIOLOGY;

ACUTE-PHASE PROTEINS; ADULT; ANIMALS; ASTROCYTES; DEMYELINATING DISEASES; FEMALE; HUMANS; LIPOCALINS; MALE; MICE; MICE, INBRED C57BL; OPTIC NEURITIS; PROTO-ONCOGENE PROTEINS;

EID: 84939524976     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16851     Document Type: Article

References (34)

1. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101-1108.
2. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944-949.
3. Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137:77-83.
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354:942-955.
5. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157:267-276.
6. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998;8:681-694.
7. Matsunaga Y, Kezuka T, An X, et al. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;53:6964-6971.
8. Remington LT, Babcock AA, Zehntner SP, Owens T. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol. 2007;170:1713-1724.
9. Ponomarev ED, Shriver LP, Maresz K, Dittel BN. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res. 2005;81:374-389.
10. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+T cells in multiple sclerosis. J Immunol. 2004;172:3893-3904.
11. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol. 1997;10:186-192.
12. Nam Y, Kim JH, Seo M, et al. Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. J Biol Chem. 2014;289: 16773-16789.
13. Marques F, Mesquita SD, Sousa JC, et al. Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci. 2012;6:33.
14. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917-921.
15. Lee S, Kim JH, Kim JH, et al. Lipocalin-2 is a chemokine inducer in the central nervous system: role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. J Biol Chem. 2011;286:43855-43870.
16. Rathore KI, Berard JL, Redensek A, et al. Lipocalin 2 plays an immunomodulatory role and has detrimental effects after spinal cord injury. J Neurosci. 2011;31:13412-13419.
17. Matsuda R, Kezuka T, Nishiyama C, et al. Interleukin-10 genetransfected mature dendritic cells suppress murine experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;53:7235-7245.
18. Guiddir T, Deghmane AE, Giorgini D, Taha MK. Lipocalin 2 in cerebrospinal fluid as a marker of acute bacterial meningitis. BMC Infect Dis. 2014;14:276.
19. Choi J, Lee HW, Suk K. Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci. 2011;305:28-33.
20. Kim JW, Lee SH, Jeong SH, et al. Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis. Tohoku J Exp Med. 2010;222:319- 327.
21. Marques F, Rodrigues AJ, Sousa JC, et al. Lipocalin 2 is a choroid plexus acute-phase protein. J Cereb Blood Flow Metab. 2008;28:450-455.
22. Guo H, Jin D, Chen X. Lipocalin 2 is a regulator of macrophage polarization and NF-kappaB/STAT3 pathway activation. Mol Endocrinol. 2014;28:1616-1628.
23. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268: 10425-10432.
24. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8:2347-2352.
25. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007;56:2533-2540.
26. Jang E, Kim JH, Lee S, et al. Phenotypic polarization of activated astrocytes: the critical role of lipocalin-2 in the classical inflammatory activation of astrocytes. J Immunol. 2013;191:5204-5219.
27. Jin M, Kim JH, Jang E, et al. Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab. 2014;34:1306-1314.
28. Jha MK, Jeon S, Jin M, Lee WH, Suk K. Acute phase protein lipocalin-2 is associated with formalin-induced nociception and pathological pain. Immune Netw. 2013;13:289-294.
29. Jang E, Lee S, Kim JH, et al. Secreted protein lipocalin-2 promotes microglial M1 polarization. FASEB J. 2013;27:1176- 1190.
30. Lee S, Park JY, Lee WH, et al. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci. 2009;29:234- 249.
31. Bi F, Huang C, Tong J, et al. Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A. 2013;110: 4069-4074.
32. Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia. 2013;61:453-465.
33. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483.
34. Berard JL, Zarruk JG, Arbour N, et al. Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia. 2012;60:1145-1159.